As of 2025-07-17, the Intrinsic Value of Korean Drug Co Ltd (014570.KQ) is 2,946.09 KRW. This 014570.KQ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 4,805.00 KRW, the upside of Korean Drug Co Ltd is -38.70%.
The range of the Intrinsic Value is 2,584.12 - 3,867.48 KRW
Based on its market price of 4,805.00 KRW and our intrinsic valuation, Korean Drug Co Ltd (014570.KQ) is overvalued by 38.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 2,584.12 - 3,867.48 | 2,946.09 | -38.7% |
| DCF (Growth 10y) | 2,411.33 - 3,067.69 | 2,602.23 | -45.8% |
| DCF (EBITDA 5y) | 5,045.40 - 6,254.19 | 5,738.34 | 19.4% |
| DCF (EBITDA 10y) | 4,896.99 - 6,334.29 | 5,669.50 | 18.0% |
| Fair Value | 1,016.68 - 1,016.68 | 1,016.68 | -78.84% |
| P/E | 577.47 - 4,390.60 | 2,270.07 | -52.8% |
| EV/EBITDA | 3,024.65 - 5,859.84 | 4,331.63 | -9.9% |
| EPV | 12,805.43 - 16,991.14 | 14,898.27 | 210.1% |
| DDM - Stable | 454.51 - 1,504.10 | 979.31 | -79.6% |
| DDM - Multi | 6,019.92 - 11,610.38 | 7,601.08 | 58.2% |
| Market Cap (mil) | 52,855.00 |
| Beta | 0.39 |
| Outstanding shares (mil) | 11.00 |
| Enterprise Value (mil) | 48,832.85 |
| Market risk premium | 5.82% |
| Cost of Equity | 6.35% |
| Cost of Debt | 4.25% |
| WACC | 6.34% |